With the completion of two Phase 3 clinical trials that showed its Epidiolex to be safe and effective, global interest in GW Pharma's (NASDAQ: GWPH) pharmaceutical-grade cannabidiol (CBD) extracted from ...read more
Growth Capitalist (https://growthcapitalist.com/2016/07/gw-pharma-epilepsy-research-in-australia-receives-6mm-government-funding-support/)
With the completion of two Phase 3 clinical trials that showed its Epidiolex to be safe and effective, global interest in GW Pharma's (NASDAQ: GWPH) pharmaceutical-grade cannabidiol (CBD) extracted from ...read more